baber/WOPTO huggingface dataset:
Patent RU-2661697-C2 (RU)
Title: Electroslag remelting method and device for its implementation
Inventor: BERSHITSKIJ IGOR MIKHAJLOVICH
IPC: C22B9/18
Filed: 2016-12-21
Granted: 2018-07-19
Abstract: FIELD: metallurgy. 
     SUBSTANCE: invention refers to the field of metallurgy, and specifically to the production of long-length high-quality ingots, for example, blank rolls. Method includes melting the main consumable electrode and additional consumable electrodes in the layer of electrically conductive slag, which is located in the receiving extended part of the portable cooled crystallizer, replacement of the main consumable electrode as it melts and drawing of the ingot in the vertical direction. Additional consumable electrodes are supplied to the electrically conductive slag layer before replacement of the main consumable electrode, they are evenly placed around the stub of the main consumable electrode, after which the main consumable electrode is disconnected from the power source and additional consumable electrodes are connected to it with 0.2–0.4 nominal power supplied through them, which is introduced through the main electrode, and the stub of the main consumable electrode is recovered after the start of melting of the additional consumable electrodes, after installing the new consumable electrode, additional electrodes are removed from the slag. Electrode holder for additional consumable electrodes is mounted on the crystallizer holder and is made up of two parts, which are installed with the possibility to rotate them in a horizontal plane relative to the common axis for coverage with the gap of the main consumable electrode and for the extraction of additional consumable electrodes during the remelting process of the mentioned main electrode. 
     EFFECT: invention allows to increase the efficiency of the technological process, to improve the quality of the ingot and to simplify the maintenance of the device. 
     2 cl, 10 dwg
Patent RU-2711535-C2 (RU)
Inventor: BABCOCK DAVID E
IPC: A61K31/7024
Filed: 2015-08-06
Granted: 2020-01-17
Abstract: Изобретение относится к медицинскому устройству, включающему покрытие, где покрытие содержит первый покровный слой, включающий олигомеризованный полифенол, и второй покровный слой, включающий синтетический полимер, выбранный из винилпирролидонсодержащего полимера, поли-N-изопропилакриламида, поли-N-винилкапролактама, полиэтиленоксида, поливинилового спирта, гидроксиэтилцеллюлозы или синтетического полимера, имеющего множество гидроксильных групп. Синтетический полимер соединен с олигомеризованным полифенолом водородными связями, а первый покровный слой расположен между поверхностью изделия и вторым покровным слоем. Кроме того, описаны способ нанесения покрытия на медицинское устройство; медицинское устройство, включающее гемостатическое покрытие; способ стимулирования свертывания; изделие, включающее покрытие, содержащее олигомеризованный полифенол; способ стимулирования адсорбции биологической макромолекулы на поверхности изделия; медицинское устройство, включающее внутреннюю поверхность; способ снижения или предотвращения налипания бактерий на внутренней поверхности медицинского устройства. 8 н. и 23 з.п. ф-лы, 9 ил., 4 пр.
Patent RU-2712560-C2 (RU)
Inventor: MARSAL DAVID
IPC: F01D11/00
Filed: 2015-10-15
Granted: 2020-01-29
Abstract: Изобретение относится к роторному узлу для турбинного двигателя, содержащему ротор с двумя последовательными ступенями (10a, 10b) ротора, оборудованными множеством подвижных лопастей (20), и кольцеобразный кожух (50) ротора, соединяющий две последовательные ступени ротора; статор, содержащий ступень (11) статора, снабженную множеством неподвижных лопастей (30) и расположенную между двумя ступенями ротора, и кольцеобразное статорное кольцо (60), установленное на неподвижные лопасти. Либо кожух ротора, либо статорное кольцо несет по меньшей мере одну щетку (51), предназначенную, чтобы взаимодействовать с истираемой дорожкой (62) на другом из кожуха ротора и статорного кольца, так что кожух ротора содержит по меньшей мере на одном из своих расположенных выше по потоку и ниже по потоку концов наклонный контактный фрагмент (154), опирающийся на наклонную несущую поверхность (173a) соответствующей ступени ротора, несущая поверхность является внешней поверхностью выступа (173), протягивающегося от фрагмента (127) основания соответствующей ступени ротора. Вследствие такой конфигурации кожух ротора и ступени ротора могут расширяться по-разному без радиальных механических напряжений, возникающих на границе между этими частями, что продлевает срок службы узла ротора. 2 н. и 13 з.п. ф-лы, 8 ил.
Patent RU-2697831-C2 (RU)
Inventor: ZEJLMAN Teo Gerrit
IPC: H05B45/59
Filed: 2015-11-03
Granted: 2019-08-21
Abstract: FIELD: lighting. 
     SUBSTANCE: invention relates to a LED lighting system and a method of controlling a LED lighting system. Result is achieved by the fact that LED lighting system (1) comprises wireless communication device (11, 12) for wireless signal transmission (D 10_11 , D 11_12 , D 4_12 , D 5_12 ) between LED lighting system (1) devices (10, 11, 12); at least one LED lamp (10) connected to a power supply source (2), wherein LED lamp (10) comprises driver device (100) with control unit (102) for controlling LED lamp (10) according to the received signal (D 10_11 ); phase cut detector configured to detect an input signal (V cut ) with phase cutoff for LED lamp (10); and protection circuit configured to prevent operation of LED lamp (10) with input signal (V cut ) with phase cutoff, if phase cutoff angle of input signal (V cut ) with phase cutoff exceeds a critical threshold, wherein said protection circuit is designed to prevent the effect of the input signal with phase cutoff on the LED lamp. Invention further describes LED lamp (10) comprising driver device (100) and a method of controlling a LED lighting system (1). 
     EFFECT: preventing premature failure or unsatisfactory operation of LED lamps as part of existing lighting devices. 
     15 cl, 6 dwg
Patent RU-2708958-C2 (RU)
Inventor: SACHERMAN KEVIN W
IPC: A61F2/16
Filed: 2015-11-10
Granted: 2019-12-12
Abstract: FIELD: medicine. 
     SUBSTANCE: group of inventions relates to medicine. Implanted devices have expandable reservoirs for delayed release of therapeutic agents. Device is made with possibility of at least partial implantation into eye and contains retaining structure and permeable element connected with and passing inside at least part of retaining structure. Porous drug release mechanism is placed in the fluid communication with the device outlet; and a reservoir which has a volume configured to enclose one or more therapeutic agents is in fluid communication with the outlet through a porous drug release mechanism. Device is at least partially installed along plant axis. Reservoir increases from the installation configuration, which has the first three-dimensional geometrical shape, to the expanded configuration, which has the second three-dimensional geometrical shape, the second three-dimensional geometric shape is located eccentrically relative to the plant axis. 
     EFFECT: application of the given group of inventions will allow to maximize volume of the reservoir and capacity, at the same time to minimize general invasiveness of the device and influence on anatomy of eyes and sight. 
     30 cl, 26 dwg, 1 tbl
Patent RU-2682644-C2 (RU)
Inventor: PLOTNIKOV EVGENIJ VLADIMIROVICH
IPC: A61P35/00
Filed: 2017-06-13
Granted: 2019-03-20
Abstract: FIELD: medicine; pharmaceuticals.SUBSTANCE: invention refers to pharmaceutical industry, namely to use of an anti-leukinetic and antibacterial pharmaceutical composition as an antioxidant and inducer of human mononuclear cell apoptosis. Use of an anti-leukemia and antibacterial pharmaceutical composition containing metronidazole, silver hexamethylene tetramine nitrate, sodium thiosulphate and water, as an antioxidant and apoptosis inducer of human mononuclear cells taken in a certain ratio.EFFECT: disclosed pharmaceutical composition has effective antioxidant activity and is an effective apoptosis inducer of human mononuclear cells.1 cl, 2 tbl, 2 ex
Patent RU-2701533-C2 (RU)
Title: Optimized nozzle for injection of pressurized water containing dissolved gas
Inventor: THOUVENOT THOMAS
IPC: C02F1/24
Filed: 2015-12-23
Granted: 2019-09-27
Abstract: FIELD: machine building. 
     SUBSTANCE: invention relates to methods and devices for flotation treatment of liquid wastes. Nozzle for injection of water under pressure containing dissolved gas, wherein said nozzle comprises: a cylindrical inlet chamber for said water, a cylindrical expansion chamber comprising an inlet communicating with said inlet chamber through an opening, and outlet, diffusion chamber with truncated cone section, communicating with outlet of said expansion chamber and expanding, starting from said expansion chamber, wherein said nozzle comprises means to rotate water flow leaving said expansion chamber. 
     EFFECT: technical result is energy dissipation and improved adhesion of bubbles with flakes. 
     14 cl, 11 dwg
Patent RU-2715683-C2 (RU)
Title: Method for controlling standing-phase damping of artificial knee joint
Inventor: SEIFERT DIRK
IPC: A61F2/68
Filed: 2016-04-15
Granted: 2020-03-02
Abstract: FIELD: medicine. 
     SUBSTANCE: invention refers to medicine, namely to a method for controlling an artificial knee joint depreciation phase. Artificial knee joint comprises an upper part, a lower part, a resistance unit and a control unit. Upper part and lower part are fixed on each other with possibility of rotation around axis of rotation. Resistance unit is located between the upper part and the lower part and has an adjusting device by means of which the damping resistance can be changed. Control unit is matched with control device and is connected to at least one sensor, wherein adjustment is carried out based on sensor data. During bending of stop phase up to final stop phase knee angle is recorded by at least one sensor and bending damping is raised to a level higher than initial bumpless damping until further bending is prevented when the specified maximum bend angle is achieved. 
     EFFECT: invention provides the possibility of adaptation to various situations during walking and a comfortable walking pattern with simultaneous maximum safety. 
     10 cl, 2 dwg
Patent RU-2687967-C2 (RU)
Inventor: ESKRIBA RUIS Pablo Visente
IPC: C07C59/42
Filed: 2012-10-08
Granted: 2019-05-17
Abstract: FIELD: chemistry.SUBSTANCE: present invention relates to enantiomer of [-] formula [-]HOOC-HOCH- (CH)- (CH=CH-CH)-(CH)-CHor pharmaceutically acceptable salts thereof.EFFECT: invention also relates to a pharmaceutical composition based on said enantiomer and to a method of treating pathologies, common etiology of which is an abnormally low level of sphingomyelin, abnormally low level of glyofibrillaric acid protein (GFKB), abnormally high level of dihydrofolate reductase (DHFS).18 cl, 17 dwg, 5 tbl, 9 ex
Patent RU-2716306-C2 (RU)
Title: Arrangement of friction lining elements in brake pads to increase contact force between friction lining elements at brake control
Inventor: NAJSSNER MATTIAS
IPC: F16D65/00
Filed: 2016-04-27
Granted: 2020-03-11
Abstract: FIELD: machine building.SUBSTANCE: for additional improvement of brake shoe for vehicle disc brake, having one bearing plate and multiple elements of friction pad arranged movably relative to bearing plate, so as to maximally eliminate brake squealing and simultaneously counter additional wear under action of winter ice and abrasive particles, it is proposed to make spring system between bearing plate and friction lining elements so that when brake control and due to the force generated by the clamping force applied to the elements of the friction pad, the contact force between at least two adjacent elements of the friction pad increased.EFFECT: technical result of the invention is weakening of brake squealing, besides, accumulation caused by winter conditions, ice and abrasive particles, for example sand and dust of abraded pads should decrease.13 cl, 4 dwg
Patent RU-2727142-C2 (RU)
Inventor: Nebolsin Vladimir Evgenevich
IPC: A61P15/08
Filed: 2016-05-26
Granted: 2020-07-21
Abstract: FIELD: medicine; pharmaceuticals.SUBSTANCE: group of inventions relates to pharmaceutical compositions comprising an effective amount of a compound of formula (I)(I)or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, to stimulate tissue regeneration, wherein tissue is selected from a group comprising tissue of pancreas, liver, lung, muscle tissue, spermatogenic tissue, testicular tissue and prostate tissue; normalizing reduced male fertility; to restore sperm motility; for reducing blood glucose in treating and/or preventing a pathological condition; for recovering the structure and function of the lung in treating and/or preventing a pathological condition; methods of tissue regeneration and blood glucose level reduction, comprising administering an effective amount of a compound of formula (I); as well as to medical applications of the compound of formula (I).EFFECT: group of inventions provides agents for regenerating various types of tissues, as well as use of said agents for treating diseases associated with dysfunction of tissues.18 cl, 5 dwg, 39 tbl, 40 ex
Patent RU-2752620-C2 (RU)
Title: Carbohydrate-modified particles and powdered compositions for immune response modulation
Inventor: BRYCE PAUL J
IPC: B82Y5/00
Filed: 2016-05-27
Granted: 2021-07-29
Abstract: FIELD: biotechnology.SUBSTANCE: group of inventions relates to modulation of immune response. The carbohydrate-modified particles encapsulating an antigen contain a biodegradable polymer material with an effective average diameter of 0.01 to 500 mcm and a carbohydrate moiety constituting an immunomodulator covalently attached to the surface of the particles, wherein the polymer material comprises polylactic acid, polyglycolic acid or a copolymer of polylactic acid and polyglycolic acid, wherein the particles induce tolerance to the antigen and the carbohydrate moiety is selected from the group consisting of heparin disaccharide II-A, chondroitin disaccharide Di-triS, antigen P1, sialyl-Lewis A, α1-3-mannobiose, α-D-N-acetylgalactosaminyl-1-3-galactose-β1-4-glucose and other moieties and combinations thereof. Also disclosed are a pharmaceutical composition for application in inducing tolerance to the antigen, a method for treatment of an immune disease or disorder in a subject, a method for production of particles, and carbohydrate-modified particles encapsulating the antigen.EFFECT: group of inventions provides carbohydrate-improved nanoparticles capable of modulating immune responses.19 cl, 23 dwg, 1 tbl, 3 ex
Patent RU-2764092-C2 (RU)
Title: Osb plate and its application
Inventor: SAUTER HARALD
IPC: E04C2/24
Filed: 2018-10-08
Granted: 2022-01-13
Abstract: FIELD: building materials.SUBSTANCE: present invention relates to a modified OSB plate with a new connecting element and to its use for wall and/or ceiling cladding. The present invention relates to an OSB plate with at least two opposite edges of the plate, in particular with two mutually opposite longitudinal edges, while the upper side of the OSB plate is equipped with at least one layer of paper, in particular one layer of cardboard paper, while each edge of the plate on the upper side of the plate contains a rounding with a radius from 3 to 10 mm, while each of two mutually opposite edges of the plate contains a recess in the form of a simple fold, while the fold on one edge of the plate is complementary to the fold on the opposite edge of the plate, and at the same time, on at least one of mutually opposite recesses in the form of folds, respectively, in particular in at least one groove, at least one tube with glue is provided.EFFECT: obtaining a modified OSB plate.12 cl, 4 dwg
Patent RU-2733114-C2 (RU)
Inventor: NIKOLAAS Arvid Randal
IPC: G16H10/60
Filed: 2017-03-20
Granted: 2020-09-29
Abstract: Изобретение относится к области информационных технологий, а именно к формированию электронных медицинских карт. Технический результат заключается в расширении арсенала средств того же назначения. Устройство для формирования медицинских записей и отчетов, включающее носитель для хранения, хранящий модель клинического протокола, содержащую шаблоны описательных клинических аннотаций, связанные с переходами между узлами в модели процесса клинического протокола, и инструмент управления процессом, выполненный с возможностью исполнения на вычислительном устройстве и имеющий: обработчик рабочего потока для исполнения пути пациента по модели процесса клинического протокола посредством прохождения узлов модели процесса клинического протокола в соответствии со специфической для пациента информацией, хранящейся в электронной медицинской карте (ЭМК), и генератор содержания для генерирования содержания описательного отчета по клиническому протоколу для пациента посредством заполнения полей шаблонов описательных клинических аннотаций. 3 н. и 12 з.п. ф-лы, 3 ил.
Patent RU-2746926-C2 (RU)
Title: ANTAGONISTIC ANTIBODIES THAT BIND TO HUMAN TGFβ1, TGFβ2 AND TGFβ3, AND THEIR USE IN TREATMENT OF LUNG FIBROSIS
Inventor: BON KHELEN
IPC: C07K16/22
Filed: 2017-06-07
Granted: 2021-04-22
Abstract: FIELD: biochemistry.SUBSTANCE: invention relates to the field of biochemistry and namely to an antagonist antibody or its binding fragment that specifically binds to human TGF-beta 1, human TGF-beta 2 and human TGF-beta 3, to a method for its production as well as to an isolated DNA sequence encoding its light and heavy chain; and compositions containing it. Also disclosed are a vector, host cell containing the above DNA sequence. The invention also relates to the use of the above antibody or a fragment thereof in the manufacture of a medicament for the treatment or prevention of a pathological disorder mediated by TGF-beta 1, 2 or 3 or which is associated with an increased level of TGF-beta 1, 2 or 3 as well as in the manufacture a medicament for the treatment or prevention of a pulmonary disorder which is mediated by TGF-beta 1, 2 or 3, or which is associated with an increased level of TGF-beta 1, 2 or 3.EFFECT: invention makes it possible to effectively treat a patient suffering from or at risk of a pathological disorder mediated by TGF-beta 1, 2 or 3, or associated with an increased level of TGF-beta 1, 2 or 3.28 cl, 13 tbl, 12 ex, 18 dwg
Patent RU-2764869-C2 (RU)
Inventor: CSENAR MARKUS
IPC: A61M5/19
Filed: 2017-10-27
Granted: 2022-01-21
Abstract: FIELD: medical equipment. 
     SUBSTANCE: invention refers to injection device (1) for simultaneous introduction of several drug preparations. Injection device (1) comprises bearing body (5), activating shell (8) surrounding bearing body (5), at least two carpules (9, 11), first driving module (13) for drug administration, locking device (14), needle device (17), needle protective element (20) and second actuated drive module (21) for needle device (17). Carpules (9, 11) are located next to each other. First drive module (13) comprises drive element (22) with number of piston rods (23, 24), which coincides with number of carp (9, 11), which form composite structural unit. At least one of piston rods (23, 24) is made in the form of a hollow cylinder and is formed closed on the piston side, note here that first driving device (26) of first drive module (13) is arranged therein. 
     EFFECT: disclosed is an injection device, in particular a syringe pen, for simultaneous administration of several drugs. 
     18 cl, 8 dwg
Patent RU-2747455-C2 (RU)
Title: Medicinal forms for external use containing cyclosporine and use thereof
Inventor: WEISS SIDNEY L
IPC: A61P27/02
Filed: 2017-02-28
Granted: 2021-05-05
Abstract: FIELD: medicine. 
     SUBSTANCE: group of inventions relates to the field of medicine, namely to ophthalmology, and is intended for treatment or prevention of keratoconjunctivitis sicca. Ophthalmological pharmaceutical form for external use includes cyclosporine; one or more from HCO-40, HCO-60, HCO-80, and HCO-100; and octoxynol-40. The components are used in the proposed amounts in accordance with different implementation variants of the pharmaceutical form. In other embodiments, methods of production of said ophthalmological pharmaceutical form are executed. Also proposed is a method of treatment or prevention of keratoconjunctivitis sicca including external administration of the described ophthalmological pharmaceutical form for external use to a subject in need thereof. 
     EFFECT: use of the group of inventions allows for a better safety profile and does not cause development of side effects such as decreased vision acuity, blurred vision, increased tear secretion, eye discharge and dysadhesion, and also allows increasing long-term stability, which in turn increases efficiency of treatment or preventing of keratoconjunctivitis sicca. 
     19 cl, 5 ex, 1 dwg
Patent RU-2763010-C2 (RU)
Title: Volumetric pump
Inventor: DI LEO VINCENZO
IPC: F04B43/08
Filed: 2018-06-13
Granted: 2021-12-24
Abstract: FIELD: pumping equipment.SUBSTANCE: invention relates to a volumetric pump. Volumetric pump (10) contains case (11) having inlet end (16) and outlet end (18), pump chamber (30) located between ends (16) and (18), at least one membrane (20) active in chamber (30) and movable between an extended configuration, in which a volume of chamber (30) is maximal, and a pulled configuration, in which a volume of chamber (30) is minimal, injection valve (46) located near end (18), inlet valve (26) containing inlet hole (27), outlet hole (28) and wall (29) that connects hole (27) with hole (28). Hole (27) is connected to end (16). Hole (28) is opened into chamber (30). At least one membrane (20), when it is in the pulled configuration, sticks to wall (29) of valve (26), and hole (28) of valve (26) is closed.EFFECT: invention is aimed at obtaining a suction height close to a theoretical maximum suction height.13 cl, 10 dwg
Patent RU-2770824-C2 (RU)
Title: Противоопухолевый агент
Inventor: UENO HIROYUKI
IPC: A61P35/00
Filed: 2018-11-28
Granted: 2022-04-22
Abstract: Группа изобретений относится к области медицины и фармацевтики и касается сульфонамидных соединений для лечения и/или предотвращения опухоли. Для этого разработана фармацевтическая композиция, содержащая эффективное количество сульфонамидного соединения, представленного формулой (I), где X1представляет собой атом кислорода; X2представляет собой атом кислорода; X3представляет собой -NH-; X4представляет собой атом водорода; R1представляет собой -C(R11)(R12)-; один из R11и R12представляет собой атом водорода, а другой представляет собой метильную группу; R2представляет собой фенильную группу, имеющую R21в качестве заместителя; R21представляет собой атом галогена или C1-C6 алкильную группу (когда присутствуют два или более из R21, R21являются одинаковыми или отличаются друг от друга); R3представляет фенильную группу, имеющую R31в качестве заместителя, или хроманильную группу, имеющую Rc в качестве заместителя; R31представляет собой атом галогена или аминокарбонильную группу (когда присутствуют два или более из R31, R31являются одинаковыми или отличаются друг от друга); Rc представляет собой атом галогена, гидроксигруппу или C1-C6 алкильную группу (когда присутствуют два или более из Rc, Rc являются одинаковыми или отличаются друг от друга) и R4представляет собой атом водорода; или его фармацевтически приемлемую соль и по меньшей мере другой противоопухолевый агент. Также раскрыты агент для усиления противоопухолевого эффекта другого противоопухолевого агента, противоопухолевый агент для лечения больного раком, получающего другой противоопухолевый агент, сульфонамидное соединение и способы лечения и/или предотвращения рака. Полученные соединения обладают активностью ингибирования рибонуклеотидредуктазы (RNR) и усиливают противоопухолевый эффект при совместном использовании с другим соединением, обладающим противоопухолевым эффектом. 16 н. и 20 з.п. ф-лы, 4 ил., 51 табл., 355 пр.